Cerenome reports interim data from leptomeningeal metastases study

Cerenome Inc. (NASDAQ:CNSY) reported interim data from its ReSPECT-LM study of REYOBIQ for leptomeningeal metastases. No severe toxicities were observed, and some patients showed tumor-cell reductions. The study is ongoing, with REYOBIQ not yet FDA-approved.

Original reporting
Published Nov 16, 2026, 12:36 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 12:48 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefTechnology
Primary signal
$CNSY
Bullish
high confidence
Mentioned
$CNSY
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$CNSYBullishLow
01

Why it matters

The interim safety profile is clean, and early tumor‑cell reductions were observed, potentially de‑risking the program.

02

Market read

Positive interim data could spark short‑term buying interest in CNSY while the broader market watches the trial's progression.

03

What to watch

Regulatory approval is still pending and the therapy is not yet FDA‑cleared, which could limit near‑term upside.

Relevance 8/10Novelty 7/10Timing: after‑hours release

Background

Cerenome is developing REYOBIQ, a rhenium‑186 radiopharmaceutical for leptomeningeal metastases, a high‑unmet‑need indication.

Company-level read

Ticker impact

$CNSYBullishHigh confidence
Context

Cerenome Inc. released interim data from its Phase 1 ReSPECT-LM study of REYOBIQ in leptomeningeal metastases patients.

Expected impact

likely upward pressure as the market prices in favorable early trial results

Evidence & confidence

First public disclosure of trial safety and efficacy signals; biotech stocks typically rally on positive early data.

Market effects

May increase interest in radiopharmaceuticals and neuro‑oncology pipelines.

Limited to US biotech investors; no broader regional effect.

Modest, confined to specialty oncology and radiopharma sectors.

Counterpoint

The data set is very small (10 patients) and lacks efficacy endpoints; investors may remain cautious.

Key entities

  • Cerenome Inc.

    Biotech firm developing radiopharmaceuticals.

  • REYOBIQ

    Investigational rhenium‑186 radiopharmaceutical.

Related articles

$CNSYMedAI 8/10

Cerenome (CNSY) Q3 2026 Earnings Call Transcript

Cerenome (CNSY) reported Q3 2026 earnings, highlighting progress in diagnostics and therapeutics. CNSide Diagnostics is on track for 1,250 annualized tests and exceeded 150M covered lives. REYOBIQ trials are advancing, with Phase II enrollment completed for ReSPECT-GBM and interim data presented for ReSPECT-LM. The company aims for mid-2027 top-line data and FDA alignment for next steps.

$CNSYMedAI 8/10

Cerenome Shares Interim REYOBIQ Data At SNO Meeting; Phase 2 Study Targeted For 2027

Cerenome (CNSY) presented interim Phase 1 data for REYOBIQ at the SNO meeting, showing no dose-limiting toxicities in 10 patients. Imaging confirmed consistent radiation delivery, and no LM progression was seen in evaluable patients at 3 and 6 months. REYOBIQ was generally well-tolerated. The company plans a Phase 2 study in 2027, subject to progress and regulatory alignment.

$CNSYMedAI 8/10

Cerenome Reports Interim REYOBIQ Data: No Dose-Limiting Toxicities in First 10 Patients

Cerenome reported interim data from the ReSPECT-LM study, showing no dose-limiting toxicities in the first 10 patients treated with REYOBIQ. One patient received three doses totaling 79.2 mCi, with consistent radiation delivery. No leptomeningeal (LM) progression was observed at three or six months, with one case at nine months. Cerenome plans a Phase 2 study in 2027, pending regulatory alignment.

$CNSYMedAI 8/10

Cerenome Reports Interim ReSPECT-LM Data Supporting Repeat Dosing of REYOBIQ™ in Leptomeningeal Metastases at the 2026 SNO Annual Meeting

CERENOME, INC. (CNSY) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Cerenome Reports Interim ReSPECT-LM Data Supporting Repeat Dosing of REYOBIQ ™ in Leptomeningeal Metastases at the 2026 SNO Annual Meeting No dose-limiting toxicities in the first 10 patients; consistent and reliable dosing of a targeted radiopharmaceutical; early di